Northwestern Proteomics Center of Excellence Partners with Quantum-Si for Webinar on Advancing Proteoform Analysis with Top-Down Mass Spectrometry and Single-Molecule Sequencing
Quantum-Si (Nasdaq: QSI) has announced an upcoming webinar titled 'Integrating Top-Down Mass Spectrometry and Single-Molecule Sequencing for Proteoform Analysis' scheduled for September 30, 2024. The event will feature Dr. Michael Caldwell from Northwestern University's Proteomics Center of Excellence and Dr. Meredith Carpenter from Quantum-Si.
The webinar will explore the integration of top-down mass spectrometry (TD-MS) with Quantum-Si's Platinum® instrument, showcasing how this combination offers unparalleled precision in detecting and characterizing proteins at the single-molecule level. Jeff Hawkins, CEO of Quantum-Si, emphasized the company's commitment to advancing proteomics through innovative technologies.
Dr. Caldwell highlighted the growing need for advanced technologies in proteoform characterization, stating that Quantum-Si's Platinum is a key part of their efforts in proteoform identification and discovery. The webinar aims to demonstrate how Next-Gen Protein Sequencing™ (NGPS) complements traditional approaches and enables novel discoveries in health and disease research.
Quantum-Si (Nasdaq: QSI) ha annunciato un imminente webinar intitolato 'Integrazione della spettrometria di massa top-down e sequenziamento di singole molecole per l'analisi dei proteoformi', programmato per il 30 settembre 2024. L'evento vedrà la partecipazione del Dr. Michael Caldwell del Centro di Eccellenza in Proteomica della Northwestern University e del Dr. Meredith Carpenter di Quantum-Si.
Il webinar esplorerà l'integrazione della spettrometria di massa top-down (TD-MS) con lstrumento Platinum® di Quantum-Si, dimostrando come questa combinazione offra una precisione senza pari nella rilevazione e caratterizzazione delle proteine a livello di singole molecole. Jeff Hawkins, CEO di Quantum-Si, ha enfatizzato l'impegno dell'azienda a promuovere la proteomica attraverso tecnologie innovative.
Il Dr. Caldwell ha sottolineato la crescente necessità di tecnologie avanzate nella caratterizzazione dei proteoformi, affermando che il Platinum di Quantum-Si è una parte fondamentale dei loro sforzi nell'identificazione e scoperta dei proteoformi. Il webinar mira a dimostrare come il Sequenziamento Proteico di Nuova Generazione™ (NGPS) completi gli approcci tradizionali e consenta nuove scoperte nella ricerca sulla salute e sulle malattie.
Quantum-Si (Nasdaq: QSI) ha anunciado un próximo seminario web titulado 'Integración de la espectrometría de masas de arriba hacia abajo y secuenciación de moléculas individuales para el análisis de proteoformas' programado para el 30 de septiembre de 2024. El evento contará con la participación del Dr. Michael Caldwell del Centro de Excelencia en Proteómica de la Universidad Northwestern y de la Dra. Meredith Carpenter de Quantum-Si.
El seminario web explorará la integración de la espectrometría de masas de arriba hacia abajo (TD-MS) con el instrumento Platinum® de Quantum-Si, mostrando cómo esta combinación ofrece una precisión sin precedentes en la detección y caracterización de proteínas a nivel de molécula única. Jeff Hawkins, CEO de Quantum-Si, enfatizó el compromiso de la empresa con el avance de la proteómica a través de tecnologías innovadoras.
El Dr. Caldwell destacó la creciente necesidad de tecnologías avanzadas en la caracterización de proteoformas, afirmando que el Platinum de Quantum-Si es una parte clave de sus esfuerzos en la identificación y descubrimiento de proteoformas. El seminario web tiene como objetivo demostrar cómo la Secuenciación de Proteínas de Nueva Generación™ (NGPS) complementa los enfoques tradicionales y permite descubrimientos novedosos en la investigación de la salud y las enfermedades.
Quantum-Si (Nasdaq: QSI)는 '단백질 형 분석을 위한 상향식 질량 분석법과 단일 분자 시퀀싱 통합'이라는 제목의 웨비나를 2024년 9월 30일에 개최할 예정이라고 발표했습니다. 이 행사에는 노스웨스턴 대학교의 단백질체학 우수 센터의 마이클 칼드웰 박사와 Quantum-Si의 메리디스 카슨 박사가 참여할 것입니다.
이 웨비나는 Quantum-Si의 Platinum® 장비와 상향식 질량 분석법(TD-MS)의 통합을 탐구하며, 이 조합이 단일 분자 수준에서 단백질을 탐지하고 특성화하는 데 있어 비할 데 없는 정밀도를 제공하는 방식을 보여줄 것입니다. Quantum-Si의 CEO인 제프 호킨스는 혁신적인 기술을 통해 단백질체학을 발전시키겠다는 회사의 의지를 강조했습니다.
칼드웰 박사는 단백질 형 특성화에 대한 고급 기술의 필요성이 증가하고 있음을 강조하며 Quantum-Si의 Platinum이 단백질 형 파악 및 발견을 위한 그들의 노력의 중요한 부분이라고 언급했습니다. 이 웨비나는 차세대 단백질 시퀀싱™(NGPS)이 전통적인 접근 방식을 어떻게 보완하고 건강 및 질병 연구에서 새로운 발견을 가능하게 하는지를 시연하는 것을 목표로 하고 있습니다.
Quantum-Si (Nasdaq: QSI) a annoncé un prochain webinaire intitulé 'Intégration de la spectrométrie de masse top-down et du séquençage de molécules uniques pour l'analyse des protéoformes', prévu pour le 30 septembre 2024. L'événement présentera le Dr. Michael Caldwell du Centre d'Excellence en Protéomique de l'Université Northwestern et le Dr. Meredith Carpenter de Quantum-Si.
Le webinaire explorera l'intégration de la spectrométrie de masse top-down (TD-MS) avec l'instrument Platinum® de Quantum-Si, démontrant comment cette combinaison offre une précision inégalée dans la détection et la caractérisation des protéines au niveau des molécules uniques. Jeff Hawkins, PDG de Quantum-Si, a souligné l'engagement de l'entreprise à faire avancer la protéomique grâce à des technologies innovantes.
Le Dr. Caldwell a mis en évidence le besoin croissant de technologies avancées dans la caractérisation des protéoformes, affirmant que le Platinum de Quantum-Si est une partie clé de leurs efforts dans l'identification et la découverte des protéoformes. Le webinaire vise à démontrer comment le Séquençage de Protéines de Nouvelle Génération™ (NGPS) complète les approches traditionnelles et permet des découvertes novatrices dans la recherche sur la santé et les maladies.
Quantum-Si (Nasdaq: QSI) hat ein kommendes Webinar mit dem Titel 'Integration von Top-Down-Massenspektrometrie und Einzelmolekülsequenzierung zur Analyse von Proteoformen' angekündigt, das für den 30. September 2024 geplant ist. Bei der Veranstaltung werden Dr. Michael Caldwell vom Proteomics Center of Excellence der Northwestern University und Dr. Meredith Carpenter von Quantum-Si teilnehmen.
Das Webinar wird die Integration der Top-Down-Massenspektrometrie (TD-MS) mit dem Platinum®-Instrument von Quantum-Si untersuchen und zeigen, wie diese Kombination unvergleichliche Präzision bei der Detektion und Charakterisierung von Proteinen auf Einzelmolekülebene bietet. Jeff Hawkins, CEO von Quantum-Si, betonte das Engagement des Unternehmens, die Proteomik durch innovative Technologien voranzutreiben.
Dr. Caldwell hob den wachsenden Bedarf an fortschrittlichen Technologien zur Charakterisierung von Proteoformen hervor und erklärte, dass das Platinum von Quantum-Si ein zentraler Bestandteil ihrer Bemühungen um die Identifizierung und Entdeckung von Proteoformen ist. Das Webinar zielt darauf ab, zu demonstrieren, wie die Next-Gen-Protein-Sequenzierung™ (NGPS) traditionelle Ansätze ergänzt und neuartige Entdeckungen in der Gesundheits- und Krankheitsforschung ermöglicht.
- Collaboration with Northwestern University's Proteomics Center of Excellence
- Showcasing integration of top-down mass spectrometry with Quantum-Si's Platinum® instrument
- Potential advancements in proteoform detection and analysis
- None.
This webinar will feature Dr. Michael Caldwell, Scientific Officer at Northwestern University’s Proteomics Center of Excellence, and Dr. Meredith Carpenter, Head of Scientific Affairs at Quantum-Si. Dr. Caldwell will provide insights into the latest advancements in proteoform analysis, illustrating how the combination of TD-MS and Quantum-Si’s Platinum offers unmatched precision in detecting and characterizing proteins at the single-molecule level.
"At Quantum-Si, we are committed to pushing the boundaries of proteomics by introducing cutting-edge technologies that provide researchers precision in protein analysis," said Jeff Hawkins, CEO of Quantum-Si. "This webinar is a unique opportunity for scientists and innovators to explore how the integration of top-down mass spectrometry and our Next-Gen Protein Sequencing™(NGPS) platform can revolutionize proteoform detection, ultimately advancing discoveries in disease research and therapeutic development."
“Proteoforms provide the greatest level of insight into protein biology, and the need for advanced technologies to accurately and comprehensively characterize them is growing,” said Dr. Caldwell. “We are very interested in new technologies and driving forward the field of proteoform identification and discovery, and Platinum is a key part of that effort." Employing NGPS for precise proteoform detection and analysis complements traditional approaches, and enables novel discoveries related to the role of proteoforms in health and disease.
Event Details:
Date: September 30, 2024
Time: 12:00PM Eastern/9:00AM Pacific
Hosted by: Select Science®
Registration Link: Enhance proteoform analysis through the integration of top-down mass spectrometry and single-molecule sequencing (selectscience.net)
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and kits and the Company’s other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240924105683/en/
Investor Contact
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
When is Quantum-Si's webinar on proteoform analysis scheduled?
What technologies will be discussed in Quantum-Si's (QSI) upcoming webinar?
Who are the featured speakers in Quantum-Si's (QSI) proteoform analysis webinar?
What is the potential impact of Quantum-Si's (QSI) technology on proteoform research?
